Zydus Cadila receives final approval for Eletriptan Hydrobromide Tablets
From USFDA
Zydus Cadila has received the final approval from the USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base). The drug which is used in treatment of migraine, will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content